The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article
Right arrow Full Text
Right arrow Full Text (PDF, 304K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Volpert, O. V.
Right arrow Articles by Bouck, N. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Volpert, O. V.
Right arrow Articles by Bouck, N. P.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© The Rockefeller University Press, 0022-1007/1998/9/1039/ $5.00
The Journal of Experimental Medicine, Volume 188, Number 6, September 21, 1998 1039-1046


Articles

Inhibition of Angiogenesis by Interleukin 4

Olga V. Volpert*, Tim Fong{ddagger}, Alisa E. Koch{ddagger}, Jeffrey D. Peterson*, Carl Waltenbaugh*, Robert I. Tepper§, and Noël P. Bouck*

From the * Department of Microbiology-Immunology and {ddagger} Department of Medicine and R.H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611; and § Millennium Pharmaceuticals Incorporated, Cambridge, Massachusetts 02139

Interleukin (IL)-4, a crucial modulator of the immune system and an active antitumor agent, is also a potent inhibitor of angiogenesis. When incorporated at concentrations of 10 ng/ml or more into pellets implanted into the rat cornea or when delivered systemically to the mouse by intraperitoneal injection, IL-4 blocked the induction of corneal neovascularization by basic fibroblast growth factor. IL-4 as well as IL-13 inhibited the migration of cultured bovine or human microvascular cells, showing unusual dose–response curves that were sharply stimulatory at a concentration of 0.01 ng/ml but inhibitory over a wide range of higher concentrations. Recombinant cytokine from mouse and from human worked equally well in vitro on bovine and human endothelial cells and in vivo in the rat, showing no species specificity. IL-4 was secreted at inhibitory levels by activated murine T helper (TH0) cells and by a line of carcinoma cells whose tumorigenicity is known to be inhibited by IL-4. Its ability to cause media conditioned by these cells to be antiangiogenic suggested that the antiangiogenic activity of IL-4 may play a role in normal physiology and contribute significantly to its demonstrated antitumor activity.

Key Words: neovascularization • tumor angiogenesis • endothelial cell • migration • cornea assay


Address correspondence to Noël Bouck, R.H. Lurie Cancer Center, Northwestern University Medical School, 303 East Chicago Avenue, Chicago, IL 60611. Phone: 312-503-5934; Fax: 312-908-1372; E-mail: n-bouck{at}nwu.edu

It is a pleasure to thank Bob Coffman of DNAX for crucial advice on in vivo dosing with IL-4 and the Schering Plough Research Institute for supplying the cytokine used for the in vivo work.

We also thank the National Institutes of Health for the grants that supported this work: CA52750 and CA64239 (N.P. Bouck), AR30692 and AR41492 (A.E. Koch) and AA08275 (C. Waltenbaugh). AEK also receives funds from the Veterans Administration Research Service, the Arthritis Foundation Illinois Chapter Wolkonsky Award for Rheumatoid Arthritis Research Grant and the Gallagher Professorship for Arthritis Research.

Abbreviations used: bFGF, basic fibroblast growth factor; FBS, fetal bovine serum; HMVEC, human dermal microvascular endothelial cells; hu, human recombinant; mu, murine recombinant; VCAM-1, vascular cell adhesion molecule 1.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS